#Florida #Cancer #Specialists #Research #Institute #Announces
Fort Myers, Fla., Oct. 26, 2022 (GLOBE NEWSWIRE) — Florida Cancer Specialists & Research Institute (FCS) pleased to announce that Josh Eaves has been appointed as Chief Development & Strategy Officer, reporting to Chief Executive Officer Nathan H. Walcker. Josh joined FCS earlier this year as Senior Vice President Corporate Development. In his new role, Josh will continue steering new business development initiatives including strategic partnerships and expansion opportunities to improve the patient experience throughout FCS while positively impacting value of the organization as a whole.
“Josh has developed a solid strategy for our practice that will support future growth and innovation, delving into new markets, partnerships and services,” remarked FCS Chief Executive Officer Nathan H. Walcker. “His continued leadership will enable us to forge ahead, keeping FCS at the forefront of oncology care on a global scale.”
Eaves is an experienced business development and sales professional, skilled at developing strategies to create regional networks that provide oncology coverage to local communities.
Prior to joining FCS, he served as Senior Vice President of Business Development for Alliance Oncology in Nashville, TN where he championed partnerships with health systems to develop oncology networks, to expand patient access and enhance patient experience. He led the business development and implementation team, driving the acquisition process from start to finish. Josh was also a driving force in efforts to deepen the scope of services in existing markets, developing cost models for bundled payments and value-based care contracts with payers.
He previously held positions with Nashville-based US Radiosurgery/Neospine prior to being acquired by Alliance Oncology in business development for stereotactic radiosurgery facilities. He began his career in business development for e+ healthcare, expanding PET/CT scanning services at an international…
Read on GNW: Florida Cancer Specialists & Research Institute Announces